Fibroblastic reticular cell (FRC)

Fibroblastic reticular cells (FRCs) are specialized stromal cells forming a three-dimensional reticular network in lymph nodes. They provide essential structural support and shape the microenvironment necessary for efficient immune cell interactions, antigen transport, and lymphocyte migration. FRCs are not single molecular targets but are defined by molecular markers (e.g., PDPN, CD31-negativity). Subsets of FRCs coordinate distinct immune niches—such as T cell zone reticular cells, B cell zone FRCs, and marginal reticular cells—to support T and B cell homeostasis, antigen presentation, chemokine production, and immune tolerance. Dysfunction or remodeling of FRC networks can contribute to pathologies including chronic infection, immunodeficiency, fibrosis, and altered tumor immunity. FRCs are under investigation for their role in cell therapies, tissue repair, and as components of engineered lymphoid organs, but are not classical drug targets. Key clarification: “Lymph node reticular cell” is not a molecule, receptor, or typical therapeutic target, but a cell type; thus, it is not a true pharmacological target, and this entry is best considered a misspecified or improperly defined target for drug discovery purposes.

Other names

Reticular cellLymph node fibroblastic reticular cellLN-FRCLymph node stromal cell (when FRCs are implied)

Not applicable for classical pharmacological targeting; cell therapy and anti-fibrotic strategies to modify FRC function; cytokine supplementation (e.g., IL-7 administration) to restore T cell homeostasis